These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30518301)

  • 1. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.
    Claudio-Campos KI; González-Santiago P; Renta JY; Rodríguez J; Carrasquillo K; Gaedigk A; Roche A; Ducongé J
    Pharmacogenomics; 2019 Jan; 20(1):3-8. PubMed ID: 30518301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-frequency variants at the
    Claudio-Campos K; Moneró-Paredes M; Hernández E; Renta J; Duconge J
    Pharmacogenomics; 2019 Aug; 20(12):891-902. PubMed ID: 31453773
    [No Abstract]   [Full Text] [Related]  

  • 3. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
    Drozda K; Wong S; Patel SR; Bress AP; Nutescu EA; Kittles RA; Cavallari LH
    Pharmacogenet Genomics; 2015 Feb; 25(2):73-81. PubMed ID: 25461246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement.
    Quinn AL; Liko I; Lee JC
    Pharmacogenomics; 2017 Jul; 18(11):1051-1057. PubMed ID: 28685643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.
    Claudio-Campos K; Labastida A; Ramos A; Gaedigk A; Renta-Torres J; Padilla D; Rivera-Miranda G; Scott SA; Ruaño G; Cadilla CL; Duconge-Soler J
    Front Pharmacol; 2017; 8():347. PubMed ID: 28638342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
    Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
    Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
    Schwartz JB; Kane L; Moore K; Wu AH
    J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
    Arwood MJ; Deng J; Drozda K; Pugach O; Nutescu EA; Schmidt S; Duarte JD; Cavallari LH
    Clin Pharmacol Ther; 2017 May; 101(5):675-683. PubMed ID: 28032893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up.
    Wypasek E; Mazur P; Bochenek M; Awsiuk M; Grudzien G; Plicner A; Undas A
    J Physiol Pharmacol; 2016 Jun; 67(3):385-93. PubMed ID: 27511999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.
    Cho SM; Lee KY; Choi JR; Lee KA
    Yonsei Med J; 2016 May; 57(3):635-40. PubMed ID: 26996562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin.
    Karnik ND; Sridharan K; Tiwari D; Gupta V
    Indian J Pharmacol; 2014; 46(5):549-50. PubMed ID: 25298588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.
    Mushiroda T; Ohnishi Y; Saito S; Takahashi A; Kikuchi Y; Saito S; Shimomura H; Wanibuchi Y; Suzuki T; Kamatani N; Nakamura Y
    J Hum Genet; 2006; 51(3):249-253. PubMed ID: 16432637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.